PM&R · 2020 · 16 citations · 26 references
MedicineUrologyBladder ManagementNeurourologyPediatric UrologyLactic Acid BacteriaNeurogenic BladderNeurogenic Bladder DysfunctionNeurogenic Lower Urinary Tract DysfunctionProbioticsUrinary IncontinenceAdult Intermittent CatheterizationLower Urinary Tract DiseaseLower Urinary Tract Symptom ManagementSpinal Cord Injury Bladder ManagementSpinal Cord Injury-related Bladder DysfunctionUrinary Symptom AssessmentUrinary Symptom ManagementUrinary Symptoms Management
OBJECTIVE: To test the effectiveness of intravesical Lactobacillus rhamnosus GG (LGG) to reduce the burden of urinary symptoms for individuals with spinal cord injury and disease (SCI/D) with neurogenic lower urinary tract dysfunction (NLUTD) who manage their bladders with intermittent catheterization (IC). DESIGN: A three-phase study (6 months each in baseline, intervention, and washout). Participants self-managed following the Self-Management Protocol using Probiotics (SMP-Pro), completing the online Urinary Symptom Questionnaire for Neurogenic Bladder-IC version (USQNB-IC) weekly. SETTING: Nationwide (United States). PARTICIPANTS: Ninety-six adults and seven children with SCI/D. INTERVENTIONS: In response to one or both of the SMP-Pro trigger urinary symptoms, "cloudier" or "foul smelling" urine, participants self-administered using a clean urinary catheter an LGG+ Normal Saline instillate once or twice in a 30-hour period. MAIN OUTCOME MEASURES: Change in USQNB-IC burden was adjusted individually according to the previous phase for four symptom types. Adjusted changes in burden between the intervention and washout phases were analyzed using one-sample t-tests. Holm correction was applied for the four types of symptoms: A, clinically actionable; B1, bladder function; B2, urine quality; and C, other. RESULTS: During the intervention phase, participants met SMP-Pro instillation criteria 3.83 times on average (range 1-20). An average of 5.6 doses of LGG were instilled. For those who instilled at least once, burdens of type A and B2 symptoms were significantly improved at washout (both adjusted P < .05). CONCLUSIONS: Self-instilled LGG seemed to improve "clinically actionable" (A) and "urine quality" (B2) symptom burden. No changes were observed for those who did not instill. This first-in-human clinical trial supports ongoing research of intravesical LGG, and the SMP-Pro for urinary symptoms.
26
A Simple Sequentially Rejective Multiple Test Procedure
Sture Holm · Scandinavian Journal of Statistics · 1979 · 21.8K citations
Thomas M. Hooton, Suzanne Bradley, Diana D. Cardenas et al. · Clinical Infectious Diseases · 2010 · 2.1K citations · Full text
Public Health, Infectious Disease Control, Infectious Diseases +16
Ann E. Stapleton, Melissa Au-Yeung, Thomas M. Hooton et al. · Clinical Infectious Diseases · 2011 · 468 citations · Full text